Skip to Main Content

Paper Details

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
Leuk Lymphoma
3
2022
Author NameAffiliation
Jason M Melear
Stephen E SpurgeonKnight Cancer Institute, Oregon Health and Sciences University
  • 1 - 2

Datasets

Release 1.2